ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GXE Galapagos

27.12
0.00 (0.00%)
17 Oct 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type
Galapagos TG:GXE Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 27.12 27.00 27.18 0.00 06:43:08

Galapagos to present at upcoming investor conferences

24/08/2022 9:01pm

GlobeNewswire Inc.


Galapagos (TG:GXE)
Historical Stock Chart


From Oct 2021 to Oct 2024

Click Here for more Galapagos Charts.
Galapagos to present at upcoming investor conferences

Mechelen, Belgium; 24 August 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that management will participate in the following upcoming investor conferences: 

  • Citi’s 17th Annual Biopharma Conference. September 8, 2022 in Boston
  • Morgan Stanley 20th Global Healthcare Conference. September 12-14, 2022 in New York
  • Bank of America Merrill Lynch Global Healthcare Conference. September 15, 2022 in London
  • KBC Securities Virtual Life Sciences Conference. September 16, 2022
  • JP Morgan CEO Call Series. September 28, 2022
  • Credit Suisse 31st Annual Healthcare Conference. November 8-10, 2022 in Rancho Palos Verdes, CA
  • Bryan Garnier Virtual Conference on Cell Therapy Innovation. November 14, 2022
  • Jefferies 2022 Global Healthcare Conference. November 16-17, 2022 in London
  • Kepler Cheuvreux Virtual Life Science Days. November 21, 2022
  • Deutsche Bank 2022 Call Series. November 30, 2022

Additional information regarding these events will be available on the investor section of the Galapagos website at glpg.com/events.

About GalapagosGalapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 3 programs in inflammation, oncology, fibrosis, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in the European Union (including Norway), Great Britain and Japan. For additional information, please visit www.glpg.com or follow us on LinkedIn or Twitter.

ContactInvestors:Sofie Van GijselHead of Investor Relations+1 781 296 1143

Sandra CauwenberghsDirector Investor Relations+32 495 58 46 63ir@glpg.com

Media:Marieke VermeerschHead of Corporate Communication+32 479 490 603media@glpg.com

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

 

Attachment

  • Galapagos to present at upcoming investor conferences

1 Year Galapagos Chart

1 Year Galapagos Chart

1 Month Galapagos Chart

1 Month Galapagos Chart

Your Recent History

Delayed Upgrade Clock